Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

lopment drug for Hepatitis C (HCV) infections. These data demonstrate that TMC435 has potent antiviral effect and an attractive safety profile, properties making TMC435 the best in class investigational HCV drug under development. - To realise the maximum commercial value in different markets, another two distribution partnering deals have been entered for Xerclear(R)/Xerese(R), an innovative treatment for cold sores, with Daewoong and Luxembourg. This is in addition to Medivir's agreement with GlaxoSmithKline for OTC sales in Europe and other key territories and the agreement with Meda for Rx sales in North America. During the ongoing preparations for this introduction to the market, the launch of Xerese(R) in North America has been confirmed for the first quarter of 2011. - The early-stage antiviral project portfolio, focusing on new approaches to treat HCV and other infectious diseases, is progressing well. Post Period End Highlights - Medivir announced in early October that new results with TMC435 will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston in late October 2010. This will be via a late breaking oral presentation on TMC435 phase 2b ongoing studies and four additional poster presentations on data regarding efficacy and safety and pharmacokinetic data of TMC435.

A comment from Ron Long, Medivir's CEO:

"Medivir has continued to make important progress in the third quarter of this year on the route towards becoming a successful specialty pharmaceutical company operating on an international stage. Our lead development product, TMC435, has blockbuster potential in the exciting Hepatitis C therapy arena. TMC435 is demonstrating extremely positive data in phase 2b trials, with clear competitive advantages. We look forward to the presentation of week-24 interim results at the AASLD meeting in Boston in October.

We have also worked hard during this quarter to ensure that we increase the
'/>"/>

SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... third quarter 2014 financial results on Wednesday, October 29, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Wednesday, October 29 ...
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... StreamVenue Healthcare has partnered its "plug and play" ... Medicine to teach, and to better manage post-surgical patient ... surgeons and physical therapists to view cases and discuss ... cohesive communication and creates a live classroom for teaching ...
... Reportlinker.com announces that a new market research ... Middle East and Africa ENT Devices Market ... Middle East and Africa ENT ... Summary GlobalData,s new report, "Middle ...
Cached Medicine Technology:StreamVenue Healthcare Connects Endoscopy Technology With Athletic Trainers 2Reportlinker Adds Middle East and Africa ENT Devices Market Outlook to 2017 2
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... is known for being the sole manufacturer of the stem ... to go public//. The company is slated to sell out ... with the Securities and Exchange Commission. ,Stem cells have ... raging about what this science can really offer. Controversy has ...
... mothers are demanding that they be allowed to breastfeed babies ... weight behind this proposal saying that 'women should feel confident ... Kidney's Private Member's Bill has called for a breastfeeding law ... was passed in March. In a survey by the NCT, ...
... parents of junior athletes seem to have a negative impact ... in the British Journal of Sports Medicine. ,The ... junior tennis coaches in the US, which looked at the ... The coaches had all spent an average of 17 years ...
... Minister Tony Clement has said that anti-virals will be made ... This was part of Canada’s preparation efforts to combat a ... everyone who is ill to receive treatment. A strategy is ... will get them." ,Several programs have been initiated to ...
... thrombosis (DVT) occurs when people sit in the same position ... blood causing clots in the legs//. The condition can be ... lungs, causing a pulmonary embolism. DVT which has long been ... up with a solution called flip seats which give passengers ...
... there is no evidence to blame phones towers, the chief ... that chance// is a more likely explanation for the Melbourne ... any other environmental exposure. . ,Professor Coates explained that ... there is usually no cause every time they happen though ...
Cached Medicine News:Health News:Parents of Junior Athletes do More Harm than Good 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: